What platform do you use for HRD testing of ovarian cancers and why?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Ovarian Cancer

Some prefer to assess HRD status using NGS with Caris or Tempus, but Myriad has the most data and an FDA indication. Discrepancies may become more pertinent as PARPi indications narrow again.

Related Questions

What toxicities related to mirvetuximab have you seen in your patients and how have you managed them?

Do you routinely give prophylactic antibiotics/steroids for patients on MEK-inhibitors (e.g., trametinib) to prevent rash/dermatitis?

How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?

Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?

What adjuvant therapy would you recommend for a patient with high grade serous ovarian cancer who has surgically confirmed unresectable disease after a partial response to 6 cycles of a platinum doublet?

Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

Has your preferred adjuvant treatment for IC mucinous ovarian cancer changed in response to the platinum chemotherapy shortage?

How should PARP inhibitors be incorporated into clinical practice in later line/maintenance of platinum-sensitive ovarian cancer for PARP inhibitor-naïve patients?

Do you personally review all imaging you order or rely judiciously on radiologist interpretation?